TG Therapeutics (TGTX) Stock Forecast & Price Target

TG Therapeutics Inc. is positioned for strong growth driven by its BRIUMVI product, which now accounts for approximately 30% of new prescriptions in the intravenous (IV) treatment market, poised to continue capturing market share from the leading competitor, Ocrevus. Recent data indicate a 6% increase in prescription volume over the past three months, suggesting growing physician adoption and patient demand for BRIUMVI. Additionally, projections estimate US revenue of $570-575 million for BRIUMVI by 2025, three years post-launch, reflecting effective market execution and the potential for substantial financial outcomes.

TG Therapeutics's outlook appears negative due to anticipated slower growth rates in revenue, as indicated by company guidance forecasting reduced growth from Q2 2025 to Q3 2025 compared to the subsequent period. This cautious projection is compounded by the competitive landscape, particularly when comparing potential revenues from BRIUMVI against established products like Kesimpta, which generated $2.2 billion in U.S. revenues within five years post-approval. Furthermore, while there have been improvements in annualized relapse rates (ARR) for patients transitioning to BRIUMVI, these developments may not be sufficient to drive revenue growth at a pace competitive with faster-growing alternatives in the market.